Meropenem Bradex (Meropenem Anhydrous)

Meropenem is used to treat serious infections caused by susceptible bacteria across several organ systems.

• Complicated intra‑abdominal infections: provides broad‑spectrum coverage against Gram‑negative, Gram‑positive and anaerobic organisms, helping to resolve infection.
• Complicated urinary tract infections: eradicates resistant uropathogens, facilitating clinical cure.
• Bacterial meningitis: penetrates the cerebrospinal fluid to achieve bactericidal activity against common meningitis pathogens.
• Hospital‑acquired pneumonia including ventilator‑associated pneumonia: offers potent activity against multidrug‑resistant Gram‑negative bacteria.
• Skin and soft‑tissue infections (including diabetic foot): delivers rapid bacterial killing to improve healing.

• Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial cell death. Its structure resists most β‑lactamases, providing activity against a wide range of Gram‑negative, Gram‑positive and anaerobic organisms.

Adverse reactions to Meropenem can vary from mild to severe and should be monitored during therapy.

Common Side Effects

• Nausea: mild gastrointestinal upset occurring in many patients.
• Diarrhea: may be watery and self‑limiting.
• Rash: mild skin erythema or pruritus.
• Headache: transient headache reported during treatment.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Clostridioides difficile‑associated colitis: severe diarrhea due to overgrowth of toxin‑producing bacteria.
• Anaphylaxis: acute, potentially life‑threatening hypersensitivity reaction.
• Renal toxicity: elevated creatinine or acute kidney injury in susceptible individuals.

When prescribing Meropenem, clinicians should consider several safety precautions to minimize risk.

• Renal impairment: adjust dose based on creatinine clearance.
• History of seizures: use with caution as the drug can lower seizure threshold.
• Hypersensitivity: avoid in patients with known allergy to β‑lactams.
• Pediatric use: dose must be calculated per kilogram body weight.
• Concomitant valproic acid therapy: monitor for decreased valproate levels and possible breakthrough seizures.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: carbapenems reduce serum valproate concentrations, increasing seizure risk.
• Probenecid: may increase meropenem plasma levels, raising toxicity potential.
• Aminoglycosides (e.g., gentamicin): combined nephrotoxic effect; monitor renal function closely.

Moderate Interactions (Monitor Closely)

• Loop diuretics (e.g., furosemide): additive renal stress, watch creatinine.
• Anticoagulants (e.g., warfarin): possible alteration of INR, check coagulation parameters.
• Oral contraceptives: theoretical reduction in efficacy; advise backup contraception.